View Item 

Show simple item record

Global clinical response in C ushing's syndrome patients treated with mifepristone
dc.contributor.authorKatznelson, Laurenceen_US
dc.contributor.authorLoriaux, D. Lynnen_US
dc.contributor.authorFeldman, Daviden_US
dc.contributor.authorBraunstein, Glenn D.en_US
dc.contributor.authorSchteingart, David E.en_US
dc.contributor.authorGross, Colemanen_US
dc.date.accessioned2014-05-21T18:03:26Z
dc.date.availableWITHHELD_13_MONTHSen_US
dc.date.available2014-05-21T18:03:26Z
dc.date.issued2014-04en_US
dc.identifier.citationKatznelson, Laurence; Loriaux, D. Lynn; Feldman, David; Braunstein, Glenn D.; Schteingart, David E.; Gross, Coleman (2014). "Global clinical response in C ushing's syndrome patients treated with mifepristone." Clinical Endocrinology 80(4): 562-569.en_US
dc.identifier.issn0300-0664en_US
dc.identifier.issn1365-2265en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/106755
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherPsychological Corporationen_US
dc.titleGlobal clinical response in C ushing's syndrome patients treated with mifepristoneen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/106755/1/cen12332.pdf
dc.identifier.doi10.1111/cen.12332en_US
dc.identifier.sourceClinical Endocrinologyen_US
dc.identifier.citedreferenceDoshi, A., Zaheer, A. & Stiller, M.J. ( 1997 ) A comparison of current acne grading systems and proposal of a novel system. International Journal of Dermatology, 36, 416 – 418.en_US
dc.identifier.citedreferenceGiraldi, F.P., Moro, M. & Cavagnini, F. ( 2003 ) Gender‐related differences in the presentation and course of Cushing's disease. Journal of Clinical Endocrinology and Metabolism, 88, 1554 – 1558.en_US
dc.identifier.citedreferenceFranconi, F., Brunelleschi, S., Steardo, L. et al. ( 2007 ) Gender differences in drug responses. Pharmaceutical Research, 55, 81 – 95.en_US
dc.identifier.citedreferenceWallia, A., Colleran, K., Purnell, J.Q. et al. ( 2013 ) Improvement in insulin sensitivity during mifepristone treatment of Cushing syndrome: early and late effects. Diabetes Care, 36, e147 – e148.en_US
dc.identifier.citedreferenceAuchus, R., McPhaul, M.J., Findling, J.W. et al. ( 2012 ) Predicting and managing hypertension and hypokalemia in Cushing syndrome during mifepristone therapy. Endocrine Reviews, 33 (03 Meeting abstracts), MON–450.en_US
dc.identifier.citedreferenceSlora, E.J., Bocian, A.B., Herman‐Giddens, H. et al. ( 2009 ). Assessing inter‐rater reliability (IRR) of Tanner staging and orchidometer use with boys: a study from PROS. Journal of Pediatric Endocrinology & Metabolism, 22, 291 – 299.en_US
dc.identifier.citedreferenceLucky, A.W., Barber, B.L., Girman, C.J. et al. ( 1996 ) A multirater validation study to assess the reliability of acne lesion counting. Journal of the American Academy of Dermatology, 35, 559 – 565.en_US
dc.identifier.citedreferenceSonino, N., Boscaro, M., Fallo, F. et al. ( 2000 ) A clinical index for rating severity in Cushing's syndrome. Psycotherapy and Psychosomatics, 69, 216 – 220.en_US
dc.identifier.citedreferenceKellner, R. ( 1972 ) Improvement criteria in drug trials with neurotic patients. Psychological Medicine, 2, 73 – 80.en_US
dc.identifier.citedreferenceLindsay, J.R., Nansel, T., Baid, S. et al. ( 2006 ) Long‐term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission. Journal of Clinical Endocrinology and Metabolism, 91, 447 – 453.en_US
dc.identifier.citedreferencevan Aken, M.O., Pereira, A.M., Biermasz, N.R. et al. ( 2005 ) Quality of life in patients after long‐term biochemical cure of Cushing's disease. Journal of Clinical Endocrinology and Metabolism, 90, 3279 – 3286.en_US
dc.identifier.citedreferenceHatch, R., Rosenfield, R.L., Kim, M.H. et al. ( 1981 ) Hirsutism: implications, etiology and management. American Journal of Obstetrics and Gynecology, 140, 815 – 830.en_US
dc.identifier.citedreferenceButler, A.A., Menant, J.C., Tiedemann, A.C. et al. ( 2009 ) Age and gender differences in seven tests of functional mobility. Journal of Neuroengineering and Rehabilitation, 6, 31.en_US
dc.identifier.citedreferenceLord, S.R., Murray, S.M., Chapman, K. et al. ( 2002 ) Speed, balance and psychological status in older people. Journal of Gerontology, 57A, M539 – M543.en_US
dc.identifier.citedreferenceMathiowetz, V., Kashman, N., Volland, G. et al. ( 1985 ) Grip and pinch strength: normative data for adults. Archives of Physical Medicine and Rehabilitation, 66, 69 – 74.en_US
dc.identifier.citedreferenceBeck, A.T., Steer, R.A. & Brown, G. ( 1996 ) Manual for the Beck Depression Inventory‐II. Psychological Corporation, San Antonio, TX.en_US
dc.identifier.citedreferenceReitan, R.M. & Wolfson, D. ( 1985 ) Halstead‐Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Neuropsychological Press, Tuscon, AZ.en_US
dc.identifier.citedreferenceTombaugh, T.N. ( 2004 ) Trail Making Test A and B: normative data stratified by age and education. Archives of Clinical Neuropsychology, 19, 203 – 214.en_US
dc.identifier.citedreferenceWare, J.E. Jr, Kosinski, M., Bjorner, J.B. et al. ( 2007 ) User's manual for the SF‐36v2™ Health Survey, 2nd edn. Quality Metric Incorporated, Lincoln, RI.en_US
dc.identifier.citedreferenceShimon, I., Ram, Z., Cohen, Z.R. et al. ( 2002 ) Transsphenoidal surgery for Cushing's disease: endocrinological follow‐up monitoring of 82 patients. Neurosurgery, 51, 57 – 61.en_US
dc.identifier.citedreferenceHammer, G.D., Tyrrell, J.B., Lamborn, K.R. et al. ( 2004 ) Transsphenoidal microsurgery for Cushing's disease: initial outcome and long‐term results. Journal of Clinical Endocrinology and Metabolism, 89, 6348 – 6357.en_US
dc.identifier.citedreferenceAtkinson, A.B., Kennedy, A., Wiggam, M.I. et al. ( 2005 ) Long‐term remission rates after pituitary surgery for Cushing's disease: the need for long‐term surveillance. Clinical Endocrinology, 63, 549 – 559.en_US
dc.identifier.citedreferenceTritos, N.A. & Biller, B.M.K. ( 2012 ) Advances in medical therapies for Cushing's syndrome. Discovery Medicine, 13, 171 – 179.en_US
dc.identifier.citedreferenceFleseriu, M. & Petersen, M. ( 2012 ) Medical management of Cushing's disease: what is in the future? Pituitary, 15, 330 – 341.en_US
dc.identifier.citedreferenceCastinetti, F., Morange, I., Jaquet, P. et al. ( 2008 ) Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. European Journal of Endocrinology, 158, 91 – 99.en_US
dc.identifier.citedreferenceColao, A., Petersenn, S., Newell‐Price, J. et al. ( 2012 ) A 12‐month phase 3 study of pasireotide in Cushing's disease. The New England Journal of Medicine, 366, 914 – 924.en_US
dc.identifier.citedreferenceFleseriu, M., Biller, B.M., Findling, J.W. et al. ( 2012 ) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism, 97, 2039 – 2049.en_US
dc.identifier.citedreferenceLandis, R.J. & Koch, G.G. ( 1977 ) The measurement of observer agreement for categorical data. Biometrics, 33, 159 – 174.en_US
dc.identifier.citedreferenceFleiss, J.L. & Cohen, J. ( 1973 ) The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educational Psychological Measurement, 33, 613 – 619.en_US
dc.identifier.citedreferencevan der Pas, R., de Herder, W.W., Hofland, L.J. et al. ( 2012 ) New developments in the medical treatment of Cushing's syndrome. Endocrine‐Related Cancer, 19, R205 – R223.en_US
dc.identifier.citedreferenceFeelders, R.A. & Hofland, L.J. ( 2013 ) Medical treatment of Cushing's disease. Journal of Clinical Endocrinology and Metabolism, 98, 425 – 438.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cen12332.pdf
Size:
224.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe its collections in a way that respects the people and communities who create, use, and are represented in them. We encourage you to Contact Us anonymously if you encounter harmful or problematic language in catalog records or finding aids. More information about our policies and practices is available at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.